RecruitingNCT00001465

Study of the Disease Process of Lymphangioleiomyomatosis

Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Enrollment

2,000 participants

Start Date

Dec 18, 1995

Study Type

OBSERVATIONAL

Conditions

Pneumothorax Lymphangioleiomyomatosis Lung Disease Tuberous Sclerosis

Summary

Pulmonary lymphangioleiomyomatosis (LAM) is a destructive lung disease typically affecting women of childbearing age. Currently, there is no effective therapy for the disease and the prognosis is poor. This study is designed to determine the disease processes involved at the level of cells and molecules, in order to develop more effective therapy. Researchers intend to identify the proteins and genes that contribute to the process of lung destruction in affected individuals.

Eligibility

Min Age: 16 YearsMax Age: 100 Years

Plain Language Summary

Simplified for easier understanding

This study is following people with lymphangioleiomyomatosis (LAM) — a rare lung disease where abnormal muscle-like cells grow in the lungs — to learn more about how the disease progresses. **You may be eligible if...** - You have a lung biopsy or CT/X-ray findings consistent with LAM - You have LAM associated with tuberous sclerosis complex (TSC) - You are a non-smoker or smoker in good health who can serve as a comparison participant - You are 16 years of age or older **You may NOT be eligible if...** - You are under 16 years of age - You have an advanced illness where the study procedures would pose significant risk - You are on continuous oxygen therapy (for certain exercise test components of the study) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEToshibia Aquilion One CT

The Toshiba Aquilion ONE CT system is currently being used for studies in both general CT radiology and CT cardiac imaging. One of the unique aspects of the Aquilion ONE CT system is its ability to acquire whole organ volume images in a single rotation by utilizing an x-ray detector that is configured as 320 detector rows with a 0.5 mm width, providing a z-axis coverage of 16 cm of anatomy. In line with the evolutionary changes to CT systems, the Aquilion ONE will be upgraded with new technology that will expand its capabilities. The changes being made to the Aquilion ONE will provide enhancements to image acquisition capabilities, reduce ionizing radiation dose, and improve subject access to the system. All of these features assist in enhancing the safety of the currently installed Aquilion ONE CT system.